BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 21364589)

  • 1. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin.
    Rachagani S; Senapati S; Chakraborty S; Ponnusamy MP; Kumar S; Smith LM; Jain M; Batra SK
    Br J Cancer; 2011 Mar; 104(6):1038-48. PubMed ID: 21364589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
    Zhang W; Li H; Yang Y; Liao J; Yang GY
    Cancer Lett; 2014 Dec; 355(2):273-80. PubMed ID: 25304374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin promotes invasion and migration of KRAS
    Wang G; Yin L; Peng Y; Gao Y; Gao H; Zhang J; Lv N; Miao Y; Lu Z
    Cell Prolif; 2019 May; 52(3):e12575. PubMed ID: 30838710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
    Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
    Verma RK; Yu W; Shrivastava A; Shankar S; Srivastava RK
    Sci Rep; 2016 Sep; 6():32743. PubMed ID: 27624879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice.
    Stark AP; Chang HH; Jung X; Moro A; Hertzer K; Xu M; Schmidt A; Hines OJ; Eibl G
    Surgery; 2015 Dec; 158(6):1564-72. PubMed ID: 26297056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Kras oncogene and pancreatic cancer: thirty years after].
    Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
    Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
    Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
    Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zebrafish reporter lines reveal in vivo signaling pathway activities involved in pancreatic cancer.
    Schiavone M; Rampazzo E; Casari A; Battilana G; Persano L; Moro E; Liu S; Leach SD; Tiso N; Argenton F
    Dis Model Mech; 2014 Jul; 7(7):883-94. PubMed ID: 24878567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes.
    Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S
    Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells.
    Saxena S; Purohit A; Varney ML; Hayashi Y; Singh RK
    BMC Cancer; 2018 Dec; 18(1):1283. PubMed ID: 30577767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.